(Total Views: 526)
Posted On: 03/22/2021 2:19:22 PM
Post# of 148936
Tech and kabonk: the issue is the FDA asked for CD16.. if CD16 has any overlap with CD12 (and it should), how are you going to justify running a study with a placebo arm, where people can get just SOC, and have Open Label Extension for the drug, where you're guaranteed to get it?
Who would sign up for the 50% chance to get nothing, being severe or critical, with nothing else working?
Something doesn't compute.. assuming we'll know more in a few hours.
Who would sign up for the 50% chance to get nothing, being severe or critical, with nothing else working?
Something doesn't compute.. assuming we'll know more in a few hours.
(9)
(0)Scroll down for more posts ▼
